🔴 Live from #EHA2026 Congress: EORTC-GIMEMA AML 21 Phase 3 trial analysis shows pre‑treatment HRQoL independently predicts survival in Older Adults with Acute Myeloid Leukemia, supporting the incorporation of PROs in fitness criteria.
#PatientReportedOutcomes
European Organisation for Research and Treatment of Cancer
